Qin Hao Pharmaceuticals' lethal therapy MAT2A inhibitor GH31 reaches global cooperation agreement with Gilead.

On February 13, the Suzhou Industrial Park Technology Investment Center brought in the company Qinhao Pharmaceutical Co., Ltd. to enter into a global cooperation agreement with Gilead Sciences, Inc. of the United States for the synthetic lethality anti-tumor project GH31. According to the agreement terms, Gilead will have exclusive rights to develop and commercialize GH31 worldwide. Qinhao Pharmaceutical will receive an initial payment of 80 million USD, and will be eligible to receive milestone payments for development, registration, and commercialization of up to 1.45 billion USD, as well as a tiered percentage of net sales as royalties.